Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27268, USA.
Peptides. 2022 Apr;150:170735. doi: 10.1016/j.peptides.2022.170735. Epub 2022 Jan 7.
Calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) are peptide hormones and their receptors play a critical role in migraine progression and blood pressure control, respectively. CGRP and AM receptors are structurally related since they are the complex of the calcitonin receptor-like receptor (CLR) with the different types of receptor activity-modifying protein (RAMP). Several crystal structures of the CGRP and AM receptor extracellular domain (ECD) used maltose-binding protein (MBP) as a tag protein to facilitate crystallization. Unexpectedly, the recent crystal structures of CGRP receptor ECD showed that the N-terminal tag MBP located in proximity of bound/mutated peptide ligands. This study provided evidence that MBP N-terminally tagged to the CGRP receptor ECD formed chemical interaction with the mutated peptide ligands. Interestingly, N-glycosylation of the CGRP receptor ECD was predicted to prevent MBP docking to the mutated peptide ligands. I found that the N-glycosylation of CLR ECD N123 was the most critical for inhibiting MBP interaction with the mutated peptide ligands. The MBP tag protein interaction was also dependent on the sequence of the peptide ligands. In contrast to the CGRP receptor, the MBP tag was not involved in peptide ligand binding at AM receptor ECD. Here, I provided evidence that N-glycosylation of the CGRP receptor ECD inhibited the tag protein interaction suggesting an additional function of N-glycosylation in the MBP-fused CGRP receptor ECD. This study reveals the importance of using tag protein-free versions of the CGRP receptor for the accurate assessment of peptide binding affinity.
降钙素基因相关肽 (CGRP) 和肾上腺髓质素 (AM) 是肽类激素,它们的受体分别在偏头痛进展和血压控制中起着关键作用。CGRP 和 AM 受体在结构上是相关的,因为它们是降钙素受体样受体 (CLR) 与不同类型的受体活性修饰蛋白 (RAMP) 的复合物。几种 CGRP 和 AM 受体细胞外结构域 (ECD) 的晶体结构使用麦芽糖结合蛋白 (MBP) 作为标签蛋白来促进结晶。出乎意料的是,最近 CGRP 受体 ECD 的晶体结构表明,N 端标签 MBP 位于结合/突变肽配体附近。这项研究提供了证据表明,MBP 标记在 CGRP 受体 ECD 的 N 端与突变肽配体形成化学相互作用。有趣的是,CGRP 受体 ECD 的 N-糖基化被预测可防止 MBP 与突变肽配体结合。我发现 CLR ECD N123 的 N-糖基化对于抑制 MBP 与突变肽配体的相互作用至关重要。MBP 标签蛋白相互作用也依赖于肽配体的序列。与 CGRP 受体不同,MBP 标签不参与 AM 受体 ECD 中的肽配体结合。在这里,我提供了证据表明,CGRP 受体 ECD 的 N-糖基化抑制了标签蛋白相互作用,这表明 N-糖基化在 MBP 融合的 CGRP 受体 ECD 中具有额外的功能。这项研究揭示了使用无标签蛋白版本的 CGRP 受体准确评估肽结合亲和力的重要性。